POSTERS & ABSTRACTS

AB928

November 29, 2018

The Dual A2aR/A2bR Antagonist AB928 Reverses Adenosine-Mediated Immune Suppression and Inhibits Tumor Growth in vivo. DiRenzo D, Piovesan D, Narasappa N, Lim WH, Ashok D, Park A, Jeffrey JL, Leleti MR, Tan JBL, Seitz L, Young SW, Powers JP, Walters MJ. American Association for Cancer Research; Tumor Immunology and Immunotherapy, Miami Beach, FL.; poster No. A10.

View Poster

November 7—November 11, 2018

Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928. DiRenzo D, Ashok D, Anderson AE, Udyavar A, Tan JBL, Zhang K, Jeffrey JL, Seitz L, Leleti MR, Young SW, Powers JP, Walters MJ. Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P35; abstract No. 10513.

View Poster

November 7—November 11, 2018

Selection of optimized drug candidates, dosing regimen, pharmacodynamic endpoints, tumor types, and biomarkers for translating inhibition of the adenosine pathway into effective anti-tumor activity. Jaen J, Powers J, Schindler U, Seitz L, Tan J, Walters M, and Young S. Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.;poster No. P668; abstract No. 10724.

View Poster

November 7—November 11, 2018

A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with chemotherapy in patients with breast or gynecologic malignancies. De Souza, Lee CK, Sjoquist K, Pan S, Idan A, Rieger A, Berry W, Jin L, Seitz L, Ashok D, Walters MJ, Piovesan D, Tan JBL, Lee SJ, Park A, DiRenzo D, Karakunnel J. Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P320; abstract No. 10688.

View Poster

November 7—November 11, 2018

A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with chemotherapy in patients with gastrointestinal malignancies. De Souza, Lee CK, Sjoquist K, Pan S, Idan A, Rieger A, Berry W, Jin L, Seitz L, Ashok D, Walters MJ, Piovesan D, Tan JBL, Lee SJ, Park A, DiRenzo D, Karakunnel J. Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P321; abstract no. 10700.

View Poster

November 7—November 11, 2018

A phase 1/1b study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, in combination with carboplatin/pemetrexed and pembrolizumab in lung cancer patients. De Souza, Lee CK, Sjoquist K, Pan S, Idan A, Rieger A, Berry W, Jin L, Seitz L, Ashok D, Walters MJ, Piovesan D, Tan JBL, Lee SJ, Park A, DiRenzo D, Karakunnel J. Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P322; abstract No. 10706.

View Poster

November 7—November 11, 2018

A phase 1 study to evaluate the safety and tolerability of AB928, a novel dual adenosine receptor antagonist, with AB122, a programmed cell death-1 inhibitor, in patients with advanced malignancies. Seitz L, Rieger A, Berry W, Jin L, Ashok D, Walters MJ, Piovesan D, Tan JBL, Lee S, Park A, DiRenzo D, Karakunnel J Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P323; abstract No. 10711.

View Poster

October 19-October 23, 2018

Final results of the Phase 1 study in healthy volunteers of AB928, a dual antagonist of the A2aR and A2bR adenosine receptors being studied as an activator of anti-tumor immune response. Seitz L, Ashok D, Leleti M, Powers J, Rosen B, Miles D, Sharif E, Jin L, Park A, Young S, Rieger A, Schindler U, Karakunnel J, Walters MJ. European Society of Medical Oncology 2018 Congress, Munich, Germany; abstract No1880P.

View Poster

September 30-October 3, 2018

AB928, a dual antagonist of the A2aR and A2bR adenosine receptors, relieves adenosine-mediated immune suppression. DiRenzo D, Piovesan D, Tan JBL, Miles DH, Leleti MR, Park T, Soriano F, Handlos B, Jeffrey J, Sharif E, Rosen B, Schindler U, Powers JP, Walters MJ. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; New York, New York; abstract No. A162.

View Poster

April 14-18, 2018

Pharmacokinetic-Pharmacodynamic relationship for AB928, a dual antagonist of the A2aR and A2bR adenosine receptors. Seitz L, Ashok D, Leleti M, Powers J, Rosen B, Miles D, Sharif E, Jin L, Park A, Young S, Soriano F, Rieger A, Karakunnel J, Walters MJ. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 3769.

View Poster

April 14-18, 2018

Combining adenosine receptor inhibition with AB928 and chemotherapy results in greater immune activation and tumor control. Walters MJ, Piovesan D, Tan JBL, DiRenzo D, Yin F, Miles D, Leleti M, Park T, Soriano F, Sharif E, Schindler U and Powers JP. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 5556.

View Poster

March 23-27, 2018

Adenosinergic Axis Provides an Anchor in Multiple Anti-tumor Combination Strategies. Tan JBL, Becker A, Piovesan D, Yin FF, Soriano F, Leleti M, Jeffrey J, Miles D, Powers JP, Schindler U, Walters MJ. Keystone Symposia on Molecular and Cell Biology: Cancer Immunotherapy: Combinations, Montreal, Canada; Abstract No. 3031.

View Poster

AB680

September 30-October 3, 2018

Preclinical Pharmacokinetic and Pharmacodynamic Characterization of AB680, a Small-Molecule CD73 Inhibitor for Cancer Immunotherapy. Tan JBL, Chen J, Ginn E, Ashok D, Anderson AE, Banuelos J, Zhang K, Pham A, Park T, Chen A, Zhao X, Jin L, Lawson KV, Jeffreys J, Kalisiak J, Leleti MR, Walters MJ, and Powers JP. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; New York, New York; abstract No. A157.

View Poster

April 14-18, 2018

CD73 inhibitors (CD73i) reverse the AMP/adenosine-mediated impairment of immune effector cell activation by Immune Checkpoint Inhibitors (ICI). Becker A, Narasappa, N, Yin F, Zhang K, Park T, Kalisiak J, Lawson K, Jeffrey J, Powers JP, Schindler U, Walters, MJ, Tan JBL. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 710.

View Poster

April 14-18, 2018

Discovery and characterization of AB680, a potent and selective small-molecule CD73 inhibitor for cancer immunotherapy. Lawson KV, Jin L, Jeffrey J, Kalisiak J, Yin F, Zhang K, Chen A, Swinarski D, Walters MJ, Young S, Schindler U, Powers JP. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 4886.

View Poster

AB122

November 7-November 11, 2018

Development of a robust, simplified method to measure receptor occupancy in peripheral blood from patients treated with a novel anti-PD1 agent, AB122. Ashok D, Piovesan D, Zhao X, Singh H, Walters MJ, Young S, Seitz L. Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P15; abstract No. 10495.

View Poster

November 7-November 11, 2018

Preliminary Results from an Ongoing Phase 1 Study of AB122, an Anti-Programmed Cell Death-1 (PD-1) Monoclonal Antibody, in Patients with Advanced Solid Tumors. De Souza, Lee CK, Sjoquist K, Pan S, Idan A, Rieger A, Berry W, Jin L, Seitz L, Ashok D, Walters MJ, Piovesan D, Tan JBL, Lee SJ, Park A, DiRenzo D, Karakunnel J. Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P673; abstract No. 10638.

View Poster

April 14-18, 2018

Preclinical characterization of GLS-010 (AB122), a fully human clinical-stage anti-PD-1 antibody. Tan JBL, Chen C, Chen K, Li G, Li J, Liu J, Singh H, Wang G, Yang B, Zhang K, Zhao X, Zheng Y. Annual Meeting of the American Association of Cancer Research; Chicago, Illinois; abstract No. 4561.

View Poster

AB154

November 7-November 11, 2018

Preclinical characterization of AB154, a fully humanized anti-TIGIT antibody, for use in combination therapies. Anderson AE, Udyavar A, Becker A, Seitz L, Singh H, Zhao X, Walker NPC, Walters MJ, Tan JBL Society for Immunotherapy of Cancer Annual Meeting, Washington, D.C.; poster No. P697; abstract No. 10538.

View Poster

September 30-October 3, 2018

Preclinical characterization of AB154, a fully humanized a-TIGIT antibody, for use in combination therapies Anderson AE, Becker A, Yin F, Singh H, Zhao X, Seitz L, Stanton R, Walker NPC, Tan J. CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; New York, New York; abstract No. A124.

View Poster